Autologous peripheral blood stem cell transplantation in children with refractory or relapsed lymphoma: results of Children's Oncology Group study A5962.
暂无分享,去创建一个
Michael M. Henry | Lynette M. Smith | J. Lynch | S. Perkins | Richard E. Harris | M. Cairo | A. Vlachos | T. Gross | A. Termuhlen | L. Harrison | P. Warkentin | R. Harris
[1] S. Armstrong,et al. NCI first International Workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on the biological considerations of hematological relapse following allogeneic stem cell transplantation unrelated to graft-versus , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[2] J. Kurtzberg,et al. Myeloablative (MAC) Autologous Stem Cell Transplantation (AutoSCT) Followed By Reduced Intensity (RIC) Allogeneic Stem Cell Transplantation (AlloSCT) In Children, Adolescents And Young Adults (CAYA) With Poor Risk Hodgkin's Lymphoma (HL): Induction Of Long Term GVHL Effect , 2010 .
[3] N. Schmitz,et al. Allogeneic hematopoietic stem cell transplantation in children and adolescents with recurrent and refractory Hodgkin lymphoma: an analysis of the European Group for Blood and Marrow Transplantation. , 2009, Blood.
[4] B. Burkhardt,et al. Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: a report from the berlin-frankfurt-muenster group. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] S. Perkins,et al. Intensive chemotherapy for systemic anaplastic large cell lymphoma in children and adolescents: Final results of children's cancer group study 5941 , 2009, Pediatric blood & cancer.
[6] K. Horibe,et al. Impact of the methotrexate administration dose on the need for intrathecal treatment in children and adolescents with anaplastic large-cell lymphoma: results of a randomized trial of the EICNHL Group. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] B. Shiramizu,et al. A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B‐cell (CD20+) non‐Hodgkin lymphoma and mature B‐cell acute lymphoblastic leukemia: A report from the Children's Oncology Group , 2009, Pediatric blood & cancer.
[8] S. Perkins,et al. Excellent survival following two courses of COPAD chemotherapy in children and adolescents with resected localized B‐cell non‐Hodgkin’s lymphoma: results of the FAB/LMB 96 international study * , 2008, British journal of haematology.
[9] M. Cairo,et al. Stem cell transplantation for pediatric lymphoma: past, present and future , 2008, Bone Marrow Transplantation.
[10] H. Lazarus,et al. Autotransplant conditioning regimens for aggressive lymphoma: are we on the right road? , 2007, Bone Marrow Transplantation.
[11] H. Atkins,et al. A 15-year analysis of early and late autologous hematopoietic stem cell transplant in relapsed, aggressive, transformed, and nontransformed follicular lymphoma. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[12] S. Perkins,et al. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. , 2007, Blood.
[13] S. Perkins,et al. Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. , 2007, Blood.
[14] S. Brain,et al. Final results of a prospective clinical trial with VAMP and low-dose involved-field radiation for children with low-risk Hodgkin's disease. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] Jeffrey S. Miller,et al. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[16] D. Maloney,et al. Immunotherapy with rituximab/interleukin-2 after autologous stem cell transplantation as treatment for CD20+ non-Hodgkin's lymphoma. , 2006, Clinical lymphoma & myeloma.
[17] B. Burkhardt,et al. Allogeneic haematopoietic stem cell transplantation in relapsed or refractory anaplastic large cell lymphoma of children and adolescents – a Berlin–Frankfurt–Münster group report , 2006, British journal of haematology.
[18] W. London,et al. APE chemotherapy for children with relapsed Hodgkin disease: A Pediatric Oncology Group trial , 2006, Pediatric blood & cancer.
[19] B. Burkhardt,et al. The impact of age and gender on biology, clinical features and treatment outcome of non‐Hodgkin lymphoma in childhood and adolescence , 2005, British journal of haematology.
[20] R. Pötter,et al. Salvage therapy of progressive and recurrent Hodgkin's disease: results from a multicenter study of the pediatric DAL/GPOH-HD study group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] N. Fineberg,et al. Augmented high-dose regimen of cyclophosphamide, carmustine, and etoposide with autologous hematopoietic stem cell transplantation for relapsed and refractory aggressive non-Hodgkin's lymphoma , 2005, Leukemia & lymphoma.
[22] N. Ueno,et al. Donor leukocyte infusions in relapsed Hodgkin's lymphoma following allogeneic stem cell transplantation: CD3+ cell dose, GVHD and disease response , 2004, Bone Marrow Transplantation.
[23] James R. Anderson,et al. Burkitt's and Burkitt‐like lymphoma in children and adolescents: a review of the Children's Cancer Group Experience * , 2003, British journal of haematology.
[24] James R. Anderson,et al. Childhood and adolescent large‐cell lymphoma (LCL): A review of the children's cancer group experience , 2003, American journal of hematology.
[25] P. Davis,et al. Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] L. Rybicki,et al. Autologous hematopoietic cell transplantation for non-Hodgkin's lymphoma: 100 month follow-up , 2002, Bone Marrow Transplantation.
[27] I. Flinn,et al. Long-term results of blood and marrow transplantation for Hodgkin's lymphoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] M. Cohen,et al. Outcomes of treatment of children and adolescents with recurrent non-Hodgkin's lymphoma and Hodgkin's disease with dexamethasone, etoposide, cisplatin, cytarabine, and l-asparaginase, maintenance chemotherapy, and transplantation: Children's Cancer Group Study CCG-5912. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] A. Romanelli,et al. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] S. Horning,et al. Autologous hematopoietic cell transplantation in Hodgkin's disease. , 2000, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[31] M. Tiemann,et al. Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report. , 2000, Blood.
[32] A. Verdeguer,et al. Autologous stem cell transplantation for advanced Hodgkin's disease in children. Spanish group for BMT in children (GETMON), Spain. , 2000, Bone marrow transplantation.
[33] A. Verdeguer,et al. Autologous stem cell transplantation for advanced Hodgkin's disease in children , 2000, Bone Marrow Transplantation.
[34] G. Delsol,et al. Relapses of childhood anaplastic large-cell lymphoma: treatment results in a series of 41 children--a report from the French Society of Pediatric Oncology. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.
[35] M. Tiemann,et al. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: A report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90. , 1999, Blood.
[36] D. Reardon,et al. MOPP or radiation in addition to ABVD in the treatment of pathologically staged advanced Hodgkin's disease in children: results of the Children's Cancer Group Phase III Trial. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] J. Shuster,et al. Treatment of children and young adults with early-stage non-Hodgkin's lymphoma. , 1997, The New England journal of medicine.
[38] R. Bouabdallah,et al. Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin’s disease: analysis of 280 patients from the French registry , 1997, Bone Marrow Transplantation.
[39] S. Horning,et al. High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: analysis of the Stanford University results and prognostic indices. , 1997, Blood.
[40] R. Bouabdallah,et al. Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin's disease: analysis of 280 patients from the French registry. Société Française de Greffe de Moëlle. , 1997, Bone marrow transplantation.
[41] J. Armitage,et al. High-dose chemotherapy followed by autologous hematopoietic rescue for Hodgkin's disease patients following first relapse after chemotherapy. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.
[42] L. Madero,et al. Bone marrow transplantation in 46 pediatric patients with non-Hodgkin's lymphoma. Spanish Working Party for Bone Marrow Transplantation in Children. , 1995, Bone marrow transplantation.
[43] D. Reece,et al. Intensive therapy with cyclophosphamide, carmustine, etoposide +/- cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy. , 1994, Blood.
[44] S. Crawford,et al. Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: the 21-year Seattle experience. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] F. Appelbaum,et al. High-dose cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation in patients with lymphoid malignancies who have received dose-limiting radiation therapy. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] James R. Anderson,et al. Long-term follow-up of patients treated with COMP or LSA2L2 therapy for childhood non-Hodgkin's lymphoma: a report of CCG-551 from the Childrens Cancer Group. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[47] J. Fay,et al. Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[48] J. Armitage,et al. High-dose cyclophosphamide, carmustine, and etoposide followed by autologous peripheral stem cell transplantation for patients with relapsed Hodgkin's disease. , 1991, Blood.
[49] S. Piantadosi,et al. Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. , 1991, Blood.
[50] D. Rosenthal,et al. Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[51] J. Armitage,et al. Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.